Scinovex
article Open AccessTop 1% cited

Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial

International Journal of Obesity · 2016 · Vol. 40(8) · pp. 1310–1319
on behalf of the SCALE study groupAdam BlackmanGary D. FosterGary ZammitRussell RosenbergLouis J. AronneThomas A. WaddenBirgitte ClaudiusCamilla JensenEmmanuel Mignot

Abstract

As an adjunct to diet and exercise, liraglutide 3.0 mg was generally well tolerated and produced significantly greater reductions than placebo in AHI, body weight, SBP and HbA1c in participants with obesity and moderate/severe OSA. The results confirm that weight loss improves OSA-related parameters.

Obstructive Sleep Apnea ResearchRegulation of Appetite and ObesityDiabetes Treatment and ManagementMedicineObstructive sleep apneaLiraglutideSleep apneaRandomized controlled trialObesityApneaSleep (system call)Internal medicineEndocrinology

MeSH terms

LiraglutideAdolescentAdultDouble-Blind MethodFemaleGlycated HemoglobinHumansHypoglycemic AgentsMaleMiddle AgedObesityProspective StudiesUnited StatesWeight LossTreatment Outcome

Funding

  • Novo Nordisk
Citations
506
FWCI
17.33
field-weighted impact
References
48
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial · Scinovex